lifestyle.newsblaze.com

Author: BAMBUSA THERAPEUTICS,Inc

Bambusa Therapeutics Presented Positive Results from the Phase 1 Multiple Ascending Dose Trial of BBT001 at the 2026 American Academy of Dermatology (AAD) Annual Meeting

April 1, 2026
Bambusa Therapeutics Appoints Todd James Chief Financial Officer

March 19, 2026
Bambusa Therapeutics Announces First Patient Dosed in Phase Ib Proof-of-Concept COPD Study of BBT002, Reinforcing Bispecific Pipeline Momentum

January 6, 2026
Bambusa Therapeutics Announces Completion of Series A-2 Financing to Accelerate Next-Generation Bispecific Programs

November 19, 2025